What is the share price of Entero Healthcare Solutions Ltd (ENTERO) today?
The share price of ENTERO as on 27th July 2026 is ₹1273.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Entero Healthcare Solutions Ltd (ENTERO) share?
The past returns of Entero Healthcare Solutions Ltd (ENTERO) share are- Past 1 week: 8.21%
- Past 1 month: 8.51%
- Past 3 months: 2.48%
- Past 6 months: 12.79%
- Past 1 year: 0.89%
- Past 3 years: N/A%
- Past 5 years: 10.77%
What are the peers or stocks similar to Entero Healthcare Solutions Ltd (ENTERO)?
The peers or stocks similar to Entero Healthcare Solutions Ltd (ENTERO) include:What is the market cap of Entero Healthcare Solutions Ltd (ENTERO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Entero Healthcare Solutions Ltd (ENTERO) is ₹5351.60 Cr as of 27th July 2026.What is the 52 week high and low of Entero Healthcare Solutions Ltd (ENTERO) share?
The 52-week high of Entero Healthcare Solutions Ltd (ENTERO) is ₹1390 and the 52-week low is ₹944.What is the PE and PB ratio of Entero Healthcare Solutions Ltd (ENTERO) stock?
The P/E (price-to-earnings) ratio of Entero Healthcare Solutions Ltd (ENTERO) is 46.52. The P/B (price-to-book) ratio is 3.02.Which sector does Entero Healthcare Solutions Ltd (ENTERO) belong to?
Entero Healthcare Solutions Ltd (ENTERO) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Entero Healthcare Solutions Ltd (ENTERO) shares?
You can directly buy Entero Healthcare Solutions Ltd (ENTERO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Entero Healthcare Solutions Ltd
ENTERO Share Price
NSE₹1,273.403.56% (+43.80)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ENTERO Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ENTERO Performance & Key Metrics
ENTERO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 46.52 | 3.02 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 44.74 | 5.90 | 0.53% |
100%
Analysts have suggested that investors can buy this stock
from 4 analysts
Price Upside
Earnings Growth
Rev. Growth
ENTERO Company Profile
Entero Healthcare Solutions is an India-based technology-driven and integrated healthcare products distribution company.
SUNPHARMA
PE Ratio
40.57
40.57
1Y Return
15.95%
15.95%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
87.23
87.23
1Y Return
38.55%
38.55%
Buy Reco %
78.57
78.57
CIPLA
PE Ratio
29.38
29.38
1Y Return
10.34%
10.34%
Buy Reco %
66.67
66.67
ZYDUSLIFE
PE Ratio
21.94
21.94
1Y Return
13.07%
13.07%
Buy Reco %
55.17
55.17
LUPIN
PE Ratio
20.32
20.32
1Y Return
22.93%
22.93%
Buy Reco %
55.56
55.56
ENTERO Sentiment Analysis
ENTERO Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ENTERO Stock Summary · June 2026
Management presented the call as a year of strong top‑line progress and deliberate margin repair, reporting full‑year revenue of INR 6,591 crore and setting FY27 targets that include roughly 23% consolidated revenue growth and an EBITDA margin goal of 5.0%. Executives emphasized expanding higher‑margin MedTech exposure—now over 15% of revenues and expected to trend toward ~20% in 2–3 years—through selective deals, partnerships and heavier commercial roles while retaining disciplined acquisition valuation (historical ~5–7x EV/EBITDA) and seller alignment; they said organic execution remains the priority and new M&A was excluded from guidance. Management credited recent gross‑margin improvement to scale procurement and an agency‑like commercial mix, but acknowledged margin and working‑capital tension from MedTech dynamics (larger depreciation from IVD placements and longer supplier credit) and an unusually high, one‑off minority interest in the quarter that should normalize next year. Near term they reiterated FY27 targets—growth, a 5.0% EBITDA margin and converting at least half of EBITDA into operating cash flow—with an effective tax rate around 22–23%.
ENTERO Stock Growth Drivers
ENTERO Stock Growth Drivers
6Delivered strong financial execution and improving returns
The company beat its near‑term targets and translated operational gains into material top‑ and bottom‑line
Rapid MedTech scaling and successful M&A integration
The company completed seven acquisitions during the year, including three MedTech deals that materially enlarged
ENTERO Stock Challenges
ENTERO Stock Challenges
8Distorted consolidated earnings from partially owned subsidiaries and elevated minority interest
Consolidated results were materially distorted in Q4 by an outsized profit contribution from a partially
Accounting recognition of put‑option liabilities depressing reported pre‑minority net worth and creating contingent cash risks
Pre‑minority net worth appeared flat despite strong reported profitability because the company applied Ind AS,
ENTERO Forecast
ENTERO Forecasts
Price
Revenue
Earnings
ENTERO Share Price Forecast
ENTERO Share Price Forecast
2026
Current
₹1,273.40
Baseline
Forecast for Jul 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹1,273.40
Baseline
Forecast for Jul 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
ENTERO Company Revenue Forecast
ENTERO Company Revenue Forecast
2026
Current
₹6.61
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹6.61
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
ENTERO Stock EPS (Earnings Per Share) Forecast
ENTERO Stock EPS (Earnings Per Share) Forecast
2026
Current
₹26.44
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹26.44
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
ENTERO
ENTERO
Income
Balance Sheet
Cash Flow
Quarterly Normal View
ENTERO Income Statement
ENTERO Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 994.42 | 1,043.33 | 1,110.47 | 1,311.97 | 1,366.49 | 1,346.35 | 1,409.64 | 1,575.74 | 1,711.13 | 1,913.94 | ||||||||||
Operating & Other expenses | 964.03 | 1,005.30 | 1,066.86 | 1,258.24 | 1,308.98 | 1,290.14 | 1,353.75 | 1,508.88 | 1,646.92 | 1,823.89 | ||||||||||
EBITDA | 30.39 | 38.03 | 43.61 | 53.73 | 57.51 | 56.21 | 55.89 | 66.86 | 64.21 | 90.05 | ||||||||||
| Depreciation/Amortization | 5.99 | 7.14 | 6.61 | 7.49 | 8.10 | 8.49 | 8.87 | 9.83 | 9.80 | 14.79 | ||||||||||
| PBIT | 24.40 | 30.89 | 37.00 | 46.24 | 49.41 | 47.72 | 47.02 | 57.03 | 54.41 | 75.26 | ||||||||||
| Interest & Other Items | 16.07 | 17.32 | 9.70 | 11.46 | 9.97 | 10.49 | 10.66 | 12.40 | 14.01 | 17.31 | ||||||||||
| PBT | 8.33 | 13.57 | 27.30 | 34.78 | 39.44 | 37.23 | 36.36 | 44.63 | 40.40 | 57.95 | ||||||||||
| Taxes & Other Items | 1.55 | -7.40 | 7.22 | 11.16 | 14.00 | 11.55 | 8.56 | 13.02 | 12.77 | 29.94 | ||||||||||
| Net Income | 6.78 | 20.97 | 20.08 | 23.62 | 25.44 | 25.68 | 27.80 | 31.61 | 27.63 | 28.01 | ||||||||||
| EPS | 4.21 | 5.73 | 4.62 | 5.43 | 5.85 | 5.91 | 6.39 | 7.26 | 6.35 | 6.44 |
ENTERO Company Updates
FY 2026FY 2026
Investor Presentation
May 25PDF
Feb 12PDF
Nov 12PDF
Aug 8PDF
ENTERO Stock Peers
ENTERO Past Performance & Peer Comparison
ENTERO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Entero Healthcare Solutions Ltd | 46.52 | 3.02 | — |
| Sun Pharmaceutical Industries Ltd | 40.57 | 5.55 | 0.82% |
| Torrent Pharmaceuticals Ltd | 87.23 | 10.73 | 0.68% |
| Cipla Ltd | 29.38 | 3.30 | 0.92% |
ENTERO Stock Price Comparison
Compare ENTERO with any stock or ETFCompare ENTERO with any stock or ETF
ENTERO
ENTERO Holdings
ENTERO Shareholdings
ENTERO Promoter Holdings Trend
ENTERO Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ENTERO Institutional Holdings Trend
ENTERO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ENTERO Shareholding Pattern
ENTERO Shareholding Pattern
ENTERO Shareholding History
ENTERO Shareholding History
Foreign Institutions
Mutual Funds Invested in ENTERO
Mutual Funds Invested in ENTERO
No mutual funds holding trends are available
Top 5 Mutual Funds holding Entero Healthcare Solutions Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 3.5075% | Percentage of the fund’s portfolio invested in the stock 0.94% | Change in the portfolio weight of the stock over the last 3 months -0.18% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 57/77 (-3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 2.0912% | Percentage of the fund’s portfolio invested in the stock 1.69% | Change in the portfolio weight of the stock over the last 3 months -0.21% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 20/47 (-4) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8819% | Percentage of the fund’s portfolio invested in the stock 1.80% | Change in the portfolio weight of the stock over the last 3 months 1.80% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 48/82 (+28) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing ENTERO stock
smallcases containing ENTERO stock
Looks like this stock is not in any smallcase yet.
ENTERO Events
ENTERO Events
ENTERO Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ENTERO has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ENTERO Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ENTERO has not given any dividends in last 5 years
ENTERO Dividends
ENTERO Dividends
Hmm, looks like data is unavailable here. Please come back after some timeENTERO Stock News & Opinions
ENTERO Stock News & Opinions
Articles & Videos
Corporate
Corporate
Entero Healthcare Solutions to convene AGMEntero Healthcare Solutions announced that the 8th Annual General Meeting(AGM) of the company will be held on 19 August 2026.
1 month agoCapital Market - Live
Earnings
Earnings
Entero Healthcare Solutions consolidated net profit rises 9.03% in the March 2026 quarterNet profit of Entero Healthcare Solutions rose 9.03% to Rs 28.01 crore in the quarter ended March 2026 as against Rs 25.69 crore during the previous quarter ended March 2025. Sales rose 42.63% to Rs 1909.93 crore in the quarter ended March 2026 as against Rs 1339.06 crore during the previous quarter ended March 2025. For the full year,net profit rose 21.32% to Rs 115.04 crore in the year ended March 2026 as against Rs 94.82 crore during the previous year ended March 2025. Sales rose 29.35% to Rs 6591.21 crore in the year ended March 2026 as against Rs 5095.78 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1909.931339.06 43 6591.215095.78 29 OPM %4.503.65 -4.033.37 - PBDT72.7445.72 59 230.81169.43 36 PBT57.9537.23 56 187.52138.74 35 NP28.0125.69 9 115.0494.82 21 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Corporate
Entero Healthcare Solutions to discuss resultsEntero Healthcare Solutions will hold a meeting of the Board of Directors of the Company on 25 May 2026.
2 months agoCapital Market - Live
Earnings
Earnings
Entero Healthcare Solutions consolidated net profit rises 8.61% in the December 2025 quarterNet profit of Entero Healthcare Solutions rose 8.61% to Rs 27.63 crore in the quarter ended December 2025 as against Rs 25.44 crore during the previous quarter ended December 2024. Sales rose 25.57% to Rs 1706.52 crore in the quarter ended December 2025 as against Rs 1359.00 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales1706.521359.00 26 OPM %3.973.68 - PBDT58.3847.54 23 PBT48.5839.44 23 NP27.6325.44 9 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Corporate
Entero Healthcare Solutions to hold board meetingEntero Healthcare Solutions will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Earnings
Entero Healthcare Solutions consolidated net profit rises 33.78% in the September 2025 quarterNet profit of Entero Healthcare Solutions rose 33.78% to Rs 31.60 crore in the quarter ended September 2025 as against Rs 23.62 crore during the previous quarter ended September 2024. Sales rose 20.78% to Rs 1570.95 crore in the quarter ended September 2025 as against Rs 1300.69 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1570.951300.69 21 OPM %3.953.26 - PBDT54.4642.27 29 PBT44.6334.78 28 NP31.6023.62 34 Powered by Capital Market - Live
8 months agoCapital Market - Live
Earnings
Earnings
Entero Healthcare Solutions standalone net profit declines 62.82% in the September 2025 quarterNet profit of Entero Healthcare Solutions declined 62.82% to Rs 5.70 crore in the quarter ended September 2025 as against Rs 15.33 crore during the previous quarter ended September 2024. Sales declined 26.24% to Rs 83.22 crore in the quarter ended September 2025 as against Rs 112.83 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales83.22112.83 -26 OPM %-15.13-5.38 - PBDT10.9322.35 -51 PBT7.6120.22 -62 NP5.7015.33 -63 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Corporate
Entero Healthcare Solutions to convene board meetingEntero Healthcare Solutions will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live
8 months agoCapital Market - Live
Earnings
Earnings
Entero Healthcare Solutions consolidated net profit rises 38.45% in the June 2025 quarterNet profit of Entero Healthcare Solutions rose 38.45% to Rs 27.80 crore in the quarter ended June 2025 as against Rs 20.08 crore during the previous quarter ended June 2024. Sales rose 27.96% to Rs 1403.82 crore in the quarter ended June 2025 as against Rs 1097.04 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales1403.821097.04 28 OPM %3.572.75 - PBDT45.2333.91 33 PBT36.3627.30 33 NP27.8020.08 38 Powered by Capital Market - Live
11 months agoCapital Market - Live
Corporate
Corporate
Entero Healthcare Solutions to discuss resultsEntero Healthcare Solutions will hold a meeting of the Board of Directors of the Company on 8 August 2025.Powered by Capital Market - Live
1 year agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 29.95%, vs industry avg of 12.48%
Over the last 5 years, market share increased from 0.63% to 1.29%